Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral DNX-2401 for recurrent or refractory pediatric and young adult high-grade brain tumors
2024-515009-24-00Phase 2Authorised
- Sponsor
- Clínica Universidad de Navarra
- Start
- May 2026
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of Ad5-D24RGD in brain cancer, glioma, embryonal tumors and 5 more, sponsored by Clínica Universidad de Navarra. Primary endpoint: Overall response rate. Planned start May 2026; status: authorised.
02
Drugs
Ad5-D24RGD
03
Conditions
brain cancergliomaembryonal tumorsmedulloblastomaAtypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on 2024-515009-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515009-24-00.